Gregory Weaver
2018 - Sevion Therapeutics
In 2018, Gregory Weaver earned a total compensation of $522.2K as Chief Financial Officer at Sevion Therapeutics, a 67% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $138,000 |
|---|---|
| Salary | $347,212 |
| Other | $37,009 |
| Total | $522,221 |
Weaver received $347.2K in salary, accounting for 66% of the total pay in 2018.
Weaver also received $138K in non-equity incentive plan and $37K in other compensation.
Rankings
In 2018, Gregory Weaver's compensation ranked 11,730th out of 14,244 executives tracked by ExecPay. In other words, Weaver earned more than 17.6% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 11,730 out of 14,244 | 18th |
Division Manufacturing | 4,732 out of 5,759 | 18th |
Major group Chemicals And Allied Products | 1,791 out of 2,122 | 16th |
Industry group Drugs | 1,525 out of 1,811 | 16th |
Industry Biological Products, Except Diagnostic Substances | 296 out of 339 | 13th |
Source: SEC filing on April 5, 2019.
Weaver's colleagues
We found three more compensation records of executives who worked with Gregory Weaver at Sevion Therapeutics in 2018.